ArticleScientific reports2025
Alterations in expression of miRNA 497 and long non-coding RNAS (XIST-TSIX) and its significant role in colorectal cancer prediction.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- FOXK1: a multifaceted regulator in metabolic reprogramming and disease progression.Biology direct · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is a common type of malignancy in Western nations with high incidence related to different factors as genetic, foods and pollution. Long non-coding RNAs (LncRNAs) play a significant role in cellular processes, oncogensis and can be used as biomarkers for cancer progression. The rationale of this study was to quantify the expression levels of miRNA 497 and LncRNAs (XIST-TSIX) as a sensitive and accurate markers for CRC diagnosis and correlated with serum FOXK1, CA19.9 and CEA compared with normal subjects. This study was carried outon100 participants, they were divided into two equal groups: Group (1): Patients were diagnosed with CRC and Group (2): Normal subjects as control. Tumor size, type, TNM staging, differentiation, levels of FOXK1and, CEA, CA19.9 were evaluated in serum. The RNA was extracted from the tissue of CRC patients for quantification expression of miRNA 497 and LncRNAs (XIST and TSIX) using qRT-PCR. Data obtained showed that, the expression levels of tissue miRNA 497, XIST, TSIX in combination with serum FOXK1, CA19.9 and CEA are good confirmatory non-invasive markers for CRC diagnosis. Sensitivity and specificity tests showed higher AUC values of miRNA 497 + XIST + TSIX + FOXK1 significantly than those of CA19.9 + CAE. It was concluded that, a rigorous assessment of these parameters could facilitate the discovery of non-invasive biomarkers for the early detection and prognosis of CRC, ultimately enhancing the protocols for early treatment decision-making.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.